Micrometastatic Cancer Cells in Lymph Nodes, Bone Marrow, and Blood Clinical Significance and Biologic Implications
被引:64
作者:
Leong, Stanley P. L.
论文数: 0引用数: 0
h-index: 0
机构:
Calif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Melanoma Program, San Francisco, CA 94115 USA
Sutter Pacific Med Fdn, San Francisco, CA 94115 USA
Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USACalif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Melanoma Program, San Francisco, CA 94115 USA
Leong, Stanley P. L.
[1
,2
,3
]
Tseng, William W.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USACalif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Melanoma Program, San Francisco, CA 94115 USA
Tseng, William W.
[4
]
机构:
[1] Calif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Melanoma Program, San Francisco, CA 94115 USA
[2] Sutter Pacific Med Fdn, San Francisco, CA 94115 USA
[3] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA
cancer metastasis;
CIRCULATING TUMOR-CELLS;
EPITHELIAL-MESENCHYMAL TRANSITION;
AMERICAN JOINT COMMITTEE;
BREAST-CANCER;
SENTINEL-NODE;
MELANOMA PATIENTS;
METASTATIC MELANOMA;
PROGNOSTIC-SIGNIFICANCE;
FREE SURVIVAL;
MOLECULAR-DETECTION;
D O I:
10.3322/caac.21217
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Cancer metastasis may be regarded as a progressive process from its inception in the primary tumor microenvironment to distant sites by way of the lymphovascular system. Although this type of tumor dissemination often occurs in an orderly fashion via the sentinel lymph node ( SLN), acting as a possible gateway to the regional lymph nodes, bone marrow, and peripheral blood and ultimately to distant metastatic sites, this is not a general rule as tumor cells may enter the blood and spread to distant sites, bypassing the SLN. Methods of detecting micrometastatic cancer cells in the SLN, bone marrow, and peripheral blood of patients have been established. Patients with cancer cells in their SLN, bone marrow, or peripheral blood have worse clinical outcomes than patients with no evidence of spread to these compartments. The presence of these cells also has important biologic implications for disease progression and the clinician's understanding of the process of cancer metastasis. Further characterization of these micrometastatic cancer cells at each stage and site of metastasis is needed to design novel selective therapies for a more "personalized" treatment. (C) 2014 American Cancer Society.